Development of soluble ULBP2-controlled NK cell therapy for COVID-19
- Funded by KAKENHI
- Total publications:0 publications
Grant number: 21K08178
Grant search
Key facts
Disease
COVID-19Start & end year
20212024Known Financial Commitments (USD)
$38,610Funder
KAKENHIPrincipal Investigator
Hiroki Chitori UnspecifiedResearch Location
JapanLead Research Institution
Tottori UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable